Table 1 Patient demographics of lung adenocarcinoma patients with stages IIIB and IV
|  | Patient demographics of lung adenocarcinoma patients with stages IIIB and IV. Survival (n = 102) | Death (n = 260) | P-value | |
|---|---|---|---|---|
Age | 65.56 ± 12.395 | 66.08 ± 12.081 | 0.712 | |
Gender | ||||
 Male | 45 (44.12%) | 132 (50.77%) | 0.256 | |
 Female | 57 (55.88%) | 128 (49.23%) |  | |
Smoking | ||||
 Yes | 32 (31.37%) | 110 (42.31%) | 0.055 | |
 None | 70 (68.63%) | 150 (57.69%) |  | |
Clinical stage | ||||
 IIIB | 17 (16.67%) | 21 (8.08%) | 0.001 | |
 IVA m1a | 30 (29.41%) | 44 (16.92%) | 0.008 | |
 IVA m1b | 37 (37.27%) | 67 (25.77%) | 0.047 | |
 IVB | 15 (14.71%) | 129 (49.62%) | < 0.001 | |
Metastases | ||||
 Lung or pleura | 54 (52.94%) | 182 (70%) | 0.002 | |
 Liver | 12 (11.76%) | 77 (29.62%) | < 0.001 | |
 Brain | 4 (3.92%) | 90 (34.62%) | < 0.001 | |
 Adrenal gland | 7 (6.86%) | 57 (21.92%) | 0.001 | |
 Bone | 36 (35.29%) | 161 (61.92%) | < 0.001 | |
EGFR | ||||
 Exon 19 deletion | 38 (37.25%) | 86 (33.08%) | 0.453 | |
 L858R | 39 (38.24%) | 74 (18.46%) | 0.071 | |
 Exon 18 mutation | 4 (3.92%) | 5 (1.92%) | 0.273 | |
 Wild type | 20 (19.61%) | 91 (35%) | 0.004 | |
 Exon 20 insertion | 1 (0.98%) | 4 (1.54%) | 0.683 | |
Treatment | ||||
 Only TKI | 41 (40.20%) | 75 (28.85%) | 0.037 | |
 Only CT | 5 (4.90%) | 47 (18.08%) | 0.001 | |
 TKI with OP | 10 (9.80%) | 6 (2.31%) | 0.002 | |
 TKI with CT | 9 (8.82%) | 45 (17.31%) | 0.042 | |
 TKI with RT | 20 (19.61%) | 36 (13.85%) | 0.174 | |
 CT with OP | 2 (1.96%) | 4 (1.54%) | 0.778 | |
 CT with RT | 14 (13.73%) | 44 (16.92%) | 0.457 | |
 TKI with CT and OP | 1 (0.98%) | 3 (1.15%) | 0.887 | |
 Ever TKI | 81 (79.41%) | 163 (62.69%) | 0.002 | |
Overall survival | 44.79 ± 16.24 | 14.63 ± 11.19 | < 0.001 | |